Kirsten Johansen, MD, director of nephrology, Hennepin Healthcare, speaks on the impact that an oral medication would have on the management of chronic kidney disease (CKD) for patients both on and not on dialysis.
There are access and accessibility issues related to injectable drugs that impede management of chronic kidney disease (CKD), and orally administered hypoxia-inducible factor–prolyl hydroxylase domain inhibitors (HIF-PHIs) may prove helpful in mitigating these challenges, said Kirsten Johansen, MD, director of nephrology, Hennepin Healthcare.
Transcript
What impact can the potential approval of an oral HIF-PHI have on the standard of care for patients with CKD on and not on dialysis?
On dialysis, I see a really big opportunity for our home dialysis patients especially, and especially patients who live in rural areas where they have to come a long way to the clinic because our current therapies are injectable. They've got to come in and get injections at least once a month, sometimes even more often than once a month. So, if they have an oral option that mitigates that, it's going to be something that's going to really help them a lot.
It's going to still be important to monitor their hemoglobin. But it's a lot easier to get hemoglobin drawn,that can be done in any clinic and many labs, but injections have to happen in either the nephrology clinic if they're not on dialysis or the dialysis facility, and that's a big deal for patients.
For the nondialysis patients, again, these issues of coming in to get an injectable medicine are just really key. Even more of them are working, or if they're older, they may be relying on their children who are trying to work to get them to the clinic for the injections. People may [overlook] it as convenience, but it's more than convenience. It's being able to get your medical care and live your life. So, we need better options and an oral option could be really helpful for that.
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Latest Advances and Updates of Treatment in the Real World at AUA
May 1st 2024The annual meeting of the American Urological Association (AUA) not only presents the newest therapies coming out but showcases the latest in how treatments are being used in the real world, said Stephen Freedland, MD, of Cedars Sinai.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Dr Kathy Zackowski Discusses the Importance of Rehabilitation Research and Trials in MS
April 26th 2024Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.
Read More